Real‐world outcomes for high‐risk non‐muscle‐invasive bladder cancer: screened patients for the <scp>BRAVO</scp> trial
Patients with HRNMIBC are at high-risk of mortality. Those choosing RC as their initial treatment have lower risks of mortality than others, although this may reflect fitness and selection.
Authors
- Aidan P. Noon (ORCID: https://orcid.org/0000-0002-5999-173X)
- Jon Griffin (ORCID: https://orcid.org/0000-0003-3969-7637)
- Derek J. Rosario (ORCID: https://orcid.org/0000-0002-9086-3592)
- Syed A. Hussain (ORCID: https://orcid.org/0000-0003-1552-511X)
- James W.F. Catto (ORCID: https://orcid.org/0000-0003-2787-8828)
- Steve Kennish
- Samantha Conroy (ORCID: https://orcid.org/0000-0001-7167-4908)
- Ibrahim Jubber (ORCID: https://orcid.org/0000-0002-4558-2521)
- Rachel Hubbard
- Ramanan Rajasundaram
- Suresh Venugopal
- Stephen Mitchell
- Susan Morgan
- Kate Linton
Institutions
- Doncaster Royal Infirmary (GB)
- Buckinghamshire Healthcare NHS Trust (GB)
- Weston Park Cancer Centre (GB)
- Royal Liverpool and Broadgreen University Hospital NHS Trust (GB)
- Chesterfield Royal Hospital NHS Foundation Trust (GB)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1111/bju.16516
- Citations
- 5
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- National Institute for Health and Care Research
- Royal College of Surgeons of England
- Urology Foundation